JP2025504863A5 - - Google Patents

Info

Publication number
JP2025504863A5
JP2025504863A5 JP2024543113A JP2024543113A JP2025504863A5 JP 2025504863 A5 JP2025504863 A5 JP 2025504863A5 JP 2024543113 A JP2024543113 A JP 2024543113A JP 2024543113 A JP2024543113 A JP 2024543113A JP 2025504863 A5 JP2025504863 A5 JP 2025504863A5
Authority
JP
Japan
Prior art keywords
lpa
disease
physiological characteristics
subject
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024543113A
Other languages
English (en)
Japanese (ja)
Other versions
JP7833044B2 (ja
JP2025504863A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/073456 external-priority patent/WO2023138689A1/zh
Publication of JP2025504863A publication Critical patent/JP2025504863A/ja
Publication of JP2025504863A5 publication Critical patent/JP2025504863A5/ja
Priority to JP2026036105A priority Critical patent/JP2026116903A/ja
Application granted granted Critical
Publication of JP7833044B2 publication Critical patent/JP7833044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024543113A 2022-01-24 2023-01-23 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法 Active JP7833044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026036105A JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022073415 2022-01-24
CNPCT/CN2022/073415 2022-01-24
PCT/CN2023/073456 WO2023138689A1 (zh) 2022-01-24 2023-01-23 抑制LPA(Apo(a))蛋白表达的组合物和方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026036105A Division JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2025504863A JP2025504863A (ja) 2025-02-19
JP2025504863A5 true JP2025504863A5 (enExample) 2025-10-21
JP7833044B2 JP7833044B2 (ja) 2026-03-18

Family

ID=87347910

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024543113A Active JP7833044B2 (ja) 2022-01-24 2023-01-23 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法
JP2026036105A Pending JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026036105A Pending JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Country Status (16)

Country Link
US (2) US20250297250A1 (enExample)
EP (1) EP4471144A4 (enExample)
JP (2) JP7833044B2 (enExample)
KR (1) KR20240135657A (enExample)
CN (1) CN118679259A (enExample)
AU (1) AU2023210010A1 (enExample)
CA (1) CA3248387A1 (enExample)
CL (1) CL2024002168A1 (enExample)
CO (1) CO2024009492A2 (enExample)
DO (1) DOP2024000141A (enExample)
IL (1) IL314060A (enExample)
JO (1) JOP20240159A1 (enExample)
MX (1) MX2024008989A (enExample)
PE (1) PE20250779A1 (enExample)
TW (1) TW202345865A (enExample)
WO (1) WO2023138689A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
AU2023404700A1 (en) * 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
CN119506275A (zh) * 2023-08-22 2025-02-25 苏州炫景生物科技有限公司 抑制lpa基因表达的双链寡核苷酸及其应用
UY40897A (es) * 2023-09-21 2025-03-31 Ionis Pharmaceuticals Inc Compuestos y métodos para inhibir lpa
WO2025082059A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 经修饰的dsRNA、双链RNAi剂及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN122514601A (zh) * 2023-11-29 2026-08-04 美国圣因生物股份有限公司 靶向Lp(a)的小干扰RNA及其用途
TW202546233A (zh) * 2024-02-05 2025-12-01 美商靖因藥業（上海）有限公司 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途
WO2025252159A1 (zh) * 2024-06-06 2025-12-11 大睿生物医药科技(上海)有限公司 调控LPA表达的dsRNA分子
WO2026026890A1 (zh) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 用于抑制LPA基因表达的siRNA及其修饰物与应用
WO2026092650A1 (zh) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 一种抑制LPA基因表达的RNAi制剂及其应用
WO2026131490A1 (en) * 2024-12-20 2026-06-25 Ribocure Pharmaceuticals Ab Oligonucleotide, oligonucleotide conjugate and composition, and use thereof
WO2026133253A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2622583A1 (en) * 2005-09-15 2007-03-22 Henrik Frydenlund Hansen Rna antagonist compounds for the inhibition of apo-b100 expression
CN101292034A (zh) * 2005-09-15 2008-10-22 桑塔里斯制药公司 抑制apo-b100表达的rna拮抗化合物
RU2624028C2 (ru) * 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
SG11201912178VA (en) * 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
CN119120476A (zh) * 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
AU2019380628B2 (en) * 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
JP7507495B2 (ja) * 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
EP3923989A1 (en) 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
JP7827623B2 (ja) * 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法
EP4229201A1 (en) * 2020-10-16 2023-08-23 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
US20250283076A1 (en) * 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) * 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
WO2024035898A2 (en) * 2022-08-11 2024-02-15 Sirius Therapeutics, Inc. Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereof

Similar Documents

Publication Publication Date Title
JP7438103B2 (ja) アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
CN111343994B (zh) 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法
JP2024543496A5 (enExample)
JP2023103244A5 (enExample)
JP4718541B2 (ja) 改良された凝固因子調節剤
JP7829035B2 (ja) アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法
JP2024535888A5 (enExample)
AU2016331084A1 (en) Compositions and methods for inhibiting gene expression of LPA
US20100297105A1 (en) Administering antisense oligonucleotides complementary to human apolipoprotein b
JP2020503070A (ja) α−１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。
KR20230104200A (ko) LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
JP2022535127A (ja) アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法
JP2024535850A5 (enExample)
JP7829478B2 (ja) Ａｐｏｃ３関連疾患および障害の処置のための方法
KR20250054795A (ko) Angptl3-관련 질환 및 장애의 치료 방법
JP2007523839A (ja) 血管新生性障害の治療法
JP2023541170A (ja) Ｚ－ａａｔタンパク質のレベルを低下させる方法
US11149274B2 (en) Methods and compositions for managing vascular conditions
JP4510451B2 (ja) Ｓｔａｔ−１依存的遺伝子の発現の調節
JP2025508324A5 (enExample)
RU2024124237A (ru) Композиция и способ для подавления экспрессии белка lpa (apo(a))
JP2022546570A5 (enExample)
EP4269586A1 (en) Targeting micro rna for treatment of heart failure with preserved ejection fraction (hfpef)
JP2023542135A (ja) Ｐｃｓｋ９阻害剤及びそれを使用した処置方法
RU2024116174A (ru) Композиции и способы для подавления экспрессии белка ангиотензиногена (agt)